$33.70
-0.10 (-0.30%)
Open$33.88
Previous Close$33.80
Day High$34.49
Day Low$33.68
52W High$47.84
52W Low$9.10
Volume—
Avg Volume670.5K
Market Cap2.06B
P/E Ratio—
EPS$-4.19
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-62.0% upside
Current
$33.70
$33.70
Target
$12.80
$12.80
$8.80
$12.80 avg
$18.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 639.02M | 671.15M | 526.83M |
| Net Income | 3.07M | 3.06M | 2.31M |
| Profit Margin | 0.5% | 0.5% | 0.4% |
| EBITDA | 3.98M | 4.67M | 3.27M |
| Free Cash Flow | 2.86M | 3.84M | 2.49M |
| Rev Growth | +2.1% | +18.5% | -6.0% |
| Debt/Equity | 0.55 | 0.45 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.99 | -0.08% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.46 | -0.92% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.37 | -1.51% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $799.26 | -0.58% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.45 | -2.07% | 40.0 | 32.33B |